



www.genfit.com

GENFIT: NEW SHARES ISSUED FOLLOWING THE CONVERSION OF BOND LOANS

Lille (France), Boston (Massachusetts, United States), October 8th, 2012 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today reports the conversion of bond loans into shares performed to date as part of the €2,000,000 convertible bond loan agreement signed with YA Global Master SPV Ltd.

A total of 441,298 new shares have been issued since the signing of this loan agreement, in early August 2012, through the two-phase conversion of 90 of the 200 bonds issued, for a total converted sum of €1,100,000 (issue premium included).

The convertible bond loans were issued following the Management Board's decision on August 1st, 2012, according to the 26th and 27th resolutions of the Shareholders' Meeting held on June 26, 2012 (see Company press release on August 3, 2012).

The first conversion into 220,702 shares was performed on September 5, 2012, at a conversion rate of €2.27 per share, issue premium included. The second conversion, performed on September 24, 2012, at a conversion rate of €2.72 per share, issue premium included, resulted in the creation of 220,596 additional shares.

As a result of these two conversions:

- The social capital of GENFIT has increased from €3,787,080.25 to € 3,897,404.75;
- The number of shares representing the social capital of GENFIT has increased by 441,298, from 15,148,321 to 15,589,619 shares;
- The outstanding sum to be converted now stands at €900,000.

The level of the Company's treasury stands at M€ 7.7, taking into account that it has exercised the lease purchase option on its laboratories, for a potential lease-back operation (see the Management Board's report to the upcoming Extraordinary Shareholders' Meeting, convened on October 31, 2012, available on the Company's web site, www.genfit.com).

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian
Ph. +33 1 7544 8740 / +336 8788 4726 – barabian@milestones.fr